Saturday 17 October 2026
Export QURE’s income statement to Excel — free account
uniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.
21.72
0.80
−3.55%
Follow QURE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.90 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 2 | 3 | 4 | 3 | 5 | 1 | 3 | 6 | 5 |
P/S ratio |
5.86 | 41.50 | 91.03 | 393.68 | 42.83 | 1.82 | 9.59 | 20.85 | 31.68 | 85.48 |
Altman Z-Score |
(2.60) | (0.78) | 3.73 | 11.71 | 6.47 | 4.69 | 1.78 | (1.46) | (2.22) | (0.80) |
Altman Z″-Score (non-manufacturers) |
(4.62) | (4.41) | (1.35) | 1.25 | (2.87) | 8.47 | 1.86 | (0.87) | (4.73) | (1.71) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.55 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(1.06) | (3.93) | (3.80) | 2.46 | 2.04 | 9.33 | 3.29 | (3.21) | (2.41) | (2.95) |
P/Operating CF |
(9.38) | (30.14) | (57.05) | (110.22) | (43.22) | (20.25) | (18.67) | (6.67) | (16.26) | (17.74) |
P/B ratio |
2.31 | 6.09 | 5.72 | 8.87 | 6.59 | 1.60 | 2.14 | 1.59 | 0.00 | 6.92 |
Price to Tangible BV |
2.68 | 6.86 | 5.91 | 9.04 | 6.69 | 1.89 | 2.61 | 2.73 | 0.00 | 13.66 |
EV/Sales |
1.38 | 30.93 | 74.08 | 347.87 | 37.47 | 0.97 | 7.31 | (11.21) | 20.32 | 50.40 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.59 | 0.00 | 0.66 | 0.00 | 0.00 |
EV/Operating CF |
(0.48) | (6.31) | (10.99) | (25.67) | (10.42) | 1.76 | (5.37) | 1.22 | (3.02) | (4.56) |
EV/FCF |
(0.39) | (5.80) | (10.41) | (24.05) | (9.74) | 1.89 | (4.72) | 1.14 | (2.93) | (4.49) |
Quick Ratio |
6.24 | 8.37 | 11.77 | 11.97 | 9.20 | 16.73 | 6.00 | 8.44 | 9.32 | 9.99 |
Current Ratio |
6.34 | 8.47 | 11.85 | 12.15 | 9.47 | 17.09 | 6.28 | 8.85 | 9.74 | 10.43 |
Net Debt/EBITDA |
1.70 | 2.17 | 2.52 | 2.99 | 1.82 | (1.43) | 1.86 | 1.90 | 1.84 | 3.36 |
Debt/Assets |
10.64% | 9.92% | 15.96% | 8.04% | 10.46% | 12.48% | 14.58% | 12.23% | 9.22% | 6.02% |
Debt/Equity |
0.32 | 0.23 | 0.24 | 0.11 | 0.15 | 0.17 | 0.22 | 0.49 | (7.60) | 0.25 |
Asset Turnover |
0.11 | 0.07 | 0.05 | 0.02 | 0.10 | 0.91 | 0.14 | 0.02 | 0.04 | 0.02 |
Operating CF/Net income |
0.98 | 0.81 | 0.91 | 0.79 | 1.08 | 0.87 | 1.14 | 0.47 | 0.76 | 0.89 |
Capex/Depreciation |
(2.82) | (0.74) | (0.34) | (1.00) | (0.89) | (2.39) | (2.07) | (0.60) | (0.27) | (0.03) |
Interest Coverage |
(33.12) | (31.96) | (40.85) | (31.80) | (32.79) | 41.56 | (12.23) | (6.81) | (2.89) | (2.99) |
| (76.61%) | (103.61%) | (61.94%) | (49.42%) | (44.10%) | 78.50% | (23.66%) | (90.24%) | (238.46%) | (207.10%) | |
| (32.40%) | (39.64%) | (34.46%) | (34.38%) | (31.69%) | 57.34% | (16.75%) | (40.15%) | (34.51%) | (28.81%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (226.63%) | 138.19% | (39.60%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(46.76%) | (44.57%) | (33.89%) | (32.57%) | (47.37%) | 51.91% | (28.09%) | (49.38%) | (64.63%) | (32.79%) |
Average Days of Receivables |
133.50 | 44.17 | 7.54 | 47.47 | 64.39 | 40.94 | 350.92 | 96.60 | 79.15 | 132.94 |
Research and Development Expense of Revenue |
288.91% | 550.64% | 662.97% | 1,301.15% | 326.28% | 27.39% | 185.56% | 1,356.21% | 530.19% | 873.85% |
Selling, General and Administrative Expense of Revenue |
103.59% | 187.95% | 224.26% | 460.71% | 113.50% | 10.74% | 51.71% | 470.81% | 194.17% | 406.61% |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.02 | 0.01 | 0.01 | 0.11 | 0.12 | 0.10 | 0.17 | 0.12 |
Share Based Compensation of Revenue |
24.76% | 78.43% | 94.90% | 240.80% | 58.19% | 4.89% | 32.12% | 221.50% | 82.08% | 109.82% |
Graham Net Nets |
0.12 | 0.08 | 0.14 | 0.09 | 0.10 | 0.44 | 0.24 | 0.08 | (0.20) | 0.02 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.65 | 0.00 | 0.00 | 3.92 | 0.00 |
Earnings Yield |
(52.47%) | (14.58%) | (8.12%) | (4.35%) | (7.78%) | 34.47% | (12.41%) | (93.51%) | (27.92%) | (14.42%) |
Free Cash Flow Yield |
(61.09%) | (12.84%) | (7.82%) | (3.67%) | (8.98%) | 28.13% | (16.16%) | (47.01%) | (21.92%) | (13.13%) |
Revenue per Share |
1.00 | 0.49 | 0.32 | 0.18 | 0.84 | 11.39 | 2.28 | 0.33 | 0.56 | 0.28 |
Operating CF per Share |
(2.88) | (2.38) | (2.13) | (2.47) | (3.03) | 6.26 | (3.10) | (3.06) | (3.76) | (3.09) |
Capex per Share |
(0.69) | (0.21) | (0.12) | (0.17) | (0.21) | (0.38) | (0.38) | (0.15) | (0.07) | (0.01) |
Free Cash Flow per Share |
(3.57) | (2.59) | (2.25) | (2.63) | (3.25) | 5.88 | (3.48) | (3.21) | (3.83) | (3.10) |
Cash per Share |
5.29 | 5.91 | 6.59 | 9.44 | 5.51 | 12.10 | 7.55 | 12.96 | 7.55 | 10.83 |
Shareholders Equity per Share |
2.54 | 3.31 | 5.04 | 8.08 | 5.49 | 12.96 | 10.19 | 4.36 | (0.14) | 3.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.54 | 3.31 | 5.04 | 8.08 | 5.49 | 12.96 | 10.19 | 4.36 | (0.14) | 3.46 |
Free Cash Flow |
(89.36) | (69.85) | (80.28) | (105.33) | (144.31) | 270.52 | (162.75) | (153.08) | (186.10) | (178.40) |
Working Capital |
121.23 | 143.55 | 216.61 | 352.58 | 231.58 | 591.48 | 400.86 | 578.18 | 350.24 | 593.07 |
Capital Expenditures |
(17.17) | (5.58) | (4.24) | (6.65) | (9.48) | (17.44) | (17.69) | (7.15) | (3.37) | (0.44) |
Net Current Asset Value |
17.31 | 42.50 | 142.28 | 258.63 | 162.42 | 414.84 | 247.82 | 27.83 | (173.00) | 29.98 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.63 | 0.00 | 0.63 | 0.00 | 0.00 |
Capex to Sales |
0.68 | 0.43 | 0.38 | 0.91 | 0.25 | 0.03 | 0.17 | 0.45 | 0.12 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.17 | 0.22 | 0.43 | 0.23 | 0.33 | 0.17 | 0.17 | 0.26 | 0.62 | 1.07 |
Cash ROIC |
(41.30%) | (25.92%) | (17.52%) | (14.29%) | (27.52%) | 21.59% | (17.47%) | (16.51%) | (45.16%) | (20.48%) |
Accounts Receivable Turnover |
3.77 | 2.43 | 12.41 | 12.34 | 9.92 | 16.03 | 1.32 | 0.30 | 5.38 | 2.74 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.29 | 0.50 | 1.55 | 2.65 | 0.27 |
Inventory Turnover |
0.00 | — | — | — | — | 0.00 | 0.90 | 1.44 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.30 | 1,199.27 | 176.39 | 143.93 | 1,119.25 |
Days of Inventory on Hand |
0.00 | — | — | — | — | 0.00 | 755.99 | 322.04 | 0.00 | 0.00 |
Average Receivables |
6.65 | 5.38 | 0.91 | 0.59 | 3.78 | 32.69 | 80.57 | 53.28 | 5.04 | 5.87 |
Average Payables |
4.79 | 4.22 | 3.35 | 4.74 | 4.73 | 3.14 | 6.74 | 8.79 | 6.91 | 6.20 |
Average Inventory |
0.48 | — | — | — | — | — | 3.70 | 9.47 | — | — |
Average Assets |
226.46 | 199.95 | 241.78 | 361.27 | 394.51 | 574.79 | 757.07 | 768.33 | 694.11 | 690.72 |
Average Common Equity |
95.78 | 76.50 | 134.48 | 251.33 | 283.48 | 419.84 | 535.89 | 341.84 | 100.46 | 96.07 |
Columns are period end dates